Table Of Content
These adjustments include charges related to goodwill and intangible asset impairments. Operating cash flow in the first quarter of 2024 was $25 million, compared to ($21) million in the prior year, primarily as a result of a lower inventory build and improved cash collections. In the first quarter of 2024, the Company paid $29 million in dividends. The Company had $291 million of cash and cash equivalents as of March 31, 2024. The Implants Signature Workflow is built to address procedural challenges that impact clinical efficiency, profitability and patient care. This is done from diagnosis and treatment planning to implant placement and augmentation to temporization and final restoration, down to final checkups and preventive procedures.
Save $200 off $1000 or more + get 10,000 bonus points on your first online order
A reconciliation of Non-GAAP measures (including organic sales, adjusted EBITDA and margin, adjusted EPS, adjusted free cash flow conversion, and segment adjusted operating income) to GAAP measures is provided below. This adjustment excludes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value. Although these costs contribute to revenue generation and will recur in future periods, their amounts are significantly impacted by the timing and size of acquisitions, and as such may not be indicative of the future performance of the Company. Adjusted earnings (loss) per diluted share (adjusted EPS) is computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona shareholders by the diluted weighted average number of common shares outstanding. The Company is maintaining its 2024 outlook for organic sales growth in the range of flat to up 1.5%, and adjusted EPS in the range of $2.00 to $2.10.
Dentsply Sirona impact of coronavirus on dental ... - Dental Tribune International
Dentsply Sirona impact of coronavirus on dental ....
Posted: Wed, 04 Mar 2020 08:00:00 GMT [source]
DS Academy launches Indirect Restorative Course Series
The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. These Non-GAAP measures may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies. [1] Organic sales growth, adjusted EBITDA, and adjusted EPS are Non-GAAP financial measures which exclude certain items. Please refer to "Non-GAAP Financial Measures" below for a description of these measures and to the tables at the end of this release for a reconciliation between GAAP and Non-GAAP measures. Adjusted gross profit is computed by excluding from gross profit the impact of any of the above adjustments on either sales or cost of sales.
Facility Tour
The Company defines adjusted free cash flow as net cash provided by operating activities minus capital expenditures during the same period, and adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted net income (loss). Management believes this Non-GAAP measure is important for use in evaluating the Company’s financial performance as it measures our ability to efficiently generate cash from our business operations relative to earnings. It should be considered in addition to, rather than as a substitute for, net income (loss) as a measure of our performance or net cash provided by operating activities as a measure of our liquidity. First quarter net sales of $953 million decreased (2.6%) (organic sales decreased (1.9%)), compared to the first quarter of 2023. Net income (loss) was $18 million, or $0.09 per share, compared to net income (loss) of ($19) million, or ($0.09) per share in the first quarter of 2023. Adjusted earnings per diluted share were $0.42, compared to $0.39 in the first quarter of 2023.
Our facilities team will help you determine if this additional space is needed and assist in the reservation process. Implant placement in spaces that are narrow in the mesiodistal dimension poses challenges related to the surgical aspect of treatment. Reach out to our customer service with any additional questions you may have.
Association of Dental Support Organizations Summit 2024
In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. About Dentsply SironaDentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care.
Based on its latest view of the macroeconomic environment, the Company believes adjusted EPS and organic sales are trending towards the low-end of both ranges. The Company is revising its anticipated reported sales to a new range of $3.91 billion to $3.97 billion, due to an additional estimated foreign currency translation headwind of $50 million. The DSAC is a multipurpose training facility, showcasing the most advanced and proven dental product solutions in a clinical setting. A comprehensive variety of clinical and technical curriculums are offered, including hands-on teaching, live lectures and on-demand webinars. Ft. space and includes classrooms, a 288-seat auditorium, seven fully-outfitted operatories and two simulation labs. The DSAC may also be booked for private trainings, conferences, workshops and special events.
Additional Meeting Space
This complete implant ecosystem supports your treatment team, connects your equipment and provides impactful results. The EV Implant FamilyThe EV Implant Family consists of three implant systems with different body shapes that share common DNA. Each design is based on clinical preference and/or patient situation, but they are unified by key features such as OsseoSpeed and EV connection. These features are supported by solid evidence of pre-clinical and clinical documentation. Each implant system is designed to stimulate the healing process and helps deliver long-term function and natural-looking esthetics.
This website is using a security service to protect itself from online attacks. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. (2) Adjusted EBITDA for 2023 has been updated to reflect the reclassification of $1 million in certain gains from hedging instruments from Interest expense to Other expense (income) in order to conform with current year presentation. These adjustments are irregular in timing, and the variability in amounts may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes. Additional meeting space is provided on the first floor of the Academy building to host breakout sessions, meetings or meals.
Dentsply Sirona buys Propel Orthodontics - Dental Tribune International
Dentsply Sirona buys Propel Orthodontics.
Posted: Wed, 09 Jun 2021 11:15:15 GMT [source]
(1) Excludes those depreciation related amounts which were included as part of the business combination related adjustments. Through our Signature Workflows, we have united insights from more than 130 years of experience in the dental industry. The Implants Signature Workflow is an outcome of this experience and uses the learnings to address your key challenges in implant dentistry.
We also have a fully-functional, live-patient operatory where we can perform procedures and broadcast them to any of our training rooms or to the 288-seat auditorium. Lab C features 16 CEREC® AI Omnicams attached to moveable arms, simulating our Intego and Teneo treatment centers. An additional 16 CEREC AF Omnicams are available to showcase our clinical CAD/CAM tabletop setup. With a screen at each station, participants can watch as their instructor demonstrates CAD/CAM technology through their own dedicated CEREC unit, their computer, or an overhead camera.
No comments:
Post a Comment